Başak Tezel

Başak Tezel

Auto-generated profile, based on publicly available information

Başak Tezel

Department of Child and Adolescents Health, Ministry of Health, General Directorate of Public Health, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2009 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
MEMurat Murat Faik Erdoğan
Murat Murat Faik Erdoğan
KAK. Ağbaht
K. Ağbaht
TAT. Altunsu
T. Altunsu
SÖS. Özbaş
S. Özbaş
FYF. Yücesan
F. Yücesan
GEG. Erdoğan
G. Erdoğan

27 December 2013 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
BTBaşak Tezel
Başak Tezel
DDDILEK DILLI
DILEK DILLI
HBHilal Bolat
Hilal Bolat
HŞHatice Şahman
Hatice Şahman
SÖSema Özbaş
Sema Özbaş
SPScientific Committee of Turkish National Newborn Screening Programme
Scientific Committee of Turkish National Newborn Screening Programme
Background: Newborn screening tests have been designed to identify infants with severe disorders that are relatively prevalent and treatable or controllable. Comparing to other countries, the incidence of these diseases are very high in Turkey where the rate of consanguineous marriage is high.Methods: In this article, it is aimed to evaluate the development and organization of newborn screening programs in Turkey which include phenylketonuria, congenital hypothyroidism and biotinidase deficiency screenings. The point reached today, limitations of the program, expectations and projects for the future are discussed.Results: Today, the point reached in screening programs of the country is appreciable. While the screening rate of the live born babies was 4,7% in 1987, this rate reached to 95% by 2008. Predicted target for newborn screening program at the strategic plan of Ministry of Health for 2010–2014 was to enhance this rate above 95% by the end of 2012. It seems that the envisaged goal has been reached.Conclusion: National newborn screening program appears to be conducted successfully and extensively as a result of political determination and performance of health care workers who are in charge of this program. Nevertheless, limited numbers of the nutrition and metabolism clinics and specialists on these branches have caused some access difficulties, waste of time, and financial loss. Therefore, special planning to improve quality and the number of the clinics would be useful.

1 September 2020 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
TGTulay Guran
Tulay Guran
BTBaşak Tezel
Başak Tezel
MÇMeltem Çakır
Meltem Çakır
AAAyşehan Akıncı
Ayşehan Akıncı
ZOZerrin Orbak
Zerrin Orbak
FDFeyza F. Darendeliler
Feyza F. Darendeliler
Turkish Directorate of Public Health introduced the first pilot screening program for congenital adrenal hyperplasia (CAH) at four cities of Turkey in 2017, and then extended the program with a slight change in screening strategy in 2018 at fourteen cities. To evaluate the performance of the extended study and update our previous outcomes. Retrospective, descriptive study. Neonates of ≥32 gestational weeks and ≥1500 gr birth weight from fourteen cities, born between May-December, 2018 were included in the study. Screening protocol included one sample two-tier testing as applied in the previous pilot study. In the first step, 17α-hydroxyprogesterone (17-OHP) was measured by fluoroimmunoassay in dried blood spots (DBS) obtained at 3-5 days of life. The cases with positive initial screening were tested by steroid profiling in DBS using a liquid chromatography-tandem mass spectrometry method to measure 17-OHP, 21-deoxycortisol (21-S), cortisol (F), 11-deoxycortisol and androstenedione as a second-tier test. The babies with a steroid ratio (21-S+17-OHP)/F of ≥0.7 (instead of previous ≥0.5 cut-off value) were referred to pediatric endocrinology clinics for diagnostic assessment. In the evaluated period, 241,083 newborns were screened. 12,321 (5.11%) required second-tier testing and 880 (0.36%) were referred for clinical assessment, twenty of whom were diagnosed with CAH (10 females, 10 males). Sixteen were diagnosed as classical 21-hydroxylase deficiency (21-OHD) CAH (12 cases with salt-wasting and 4 cases with simple virilising), four cases were identified with 11β-hydroxylase deficiency (11β-OHD) CAH. No patients with salt-wasting CAH were missed by neonatal screening (sensitivity was 100%). The incidence of classical 21-OHD and 11β-OHD in the screened population was 1:15,067 and 1:60,270, respectively. Turkish neonatal CAH screening effectively leads to the early diagnosis of 21-OHD and 11β-OHD by the use of steroid profiling as a second-tier test allowing for better care of these patients in the future.

1 March 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Closed access
TGTulay Guran
Tulay Guran
BTBaşak Tezel
Başak Tezel
FGFatih Gürbüz
Fatih Gürbüz
BEBeray Selver Eklioğlu
Beray Selver Eklioğlu
NHNihal Hatipoglu
Nihal Hatipoglu
FDFeyza F. Darendeliler
Feyza F. Darendeliler

1 June 2016 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
NÇNilgün Çaylan
Nilgün Çaylan
BTBaşak Tezel
Başak Tezel
SÖSema Özbaş
Sema Özbaş
NŞNuran Şahin
Nuran Şahin
ŞAŞirin Aydın
Şirin Aydın
BKBekir Keskinkılıç
Bekir Keskinkılıç
Thyroid-stimulating hormone (TSH) level in neonates is recommended as an indicator for presence of iodine deficiency (ID) at a population level and as a monitoring tool in programs of iodine supplementation. The purpose of this study, based on data from the National Newborn Screening Program (NNSP) for congenital hypothyroidism (CH) in 2014, was to analyze neonatal TSH levels to predict the current status of iodine nutrition in Turkey. According to screening methodology, heel-prick blood samples of newborns were collected on filter paper cards usually on day 3-5 after birth (or shortly before discharge). Results of samples collected >48 h after birth were analyzed. The degree of severity of ID was assessed by using the epidemiologic criteria of the World Health Organization (WHO). Elevated TSH levels (>5 mIU/L) were processed and classified according to province, region, birth season, and sampling time. A total of 1,298531 newborns were registered in the NNSP for the CH database. Of those, 1,270311 newborns had screening results collected >48 h after birth and were included in the statistical analyses. The national prevalence of elevated TSH was 7.2%. While the Gaziantep sub-region had the highest TSH elevation rate (15.9%), the Tekirdağ sub-region had the lowest rate (4.0%; p<0.001). Seasonal variations were also significant, and the elevated TSH prevalence rate was highest in winter (7.4%; p<0.001). National CH screening results suggest that Turkey may still be mildly iodine deficient. Nationwide studies should be performed for direct assessment and monitoring of iodine status in vulnerable populations to confirm accuracy of our results.

28 March 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
YÖY. Özer
Y. Özer
AAAhmet Anık
Ahmet Anık
USUgurcan Sayili
Ugurcan Sayili
UTU. Tercan
U. Tercan
RSR. Deveci Sevim
R. Deveci Sevim
OEOlcay Evliyaoglu
Olcay Evliyaoglu
Purpose: We aimed to determine the frequency of transient congenital hypothyroidism (TCH) in 17 participating centers in Türkiye, evaluate the etiological distribution in permanent congenital hypothyroidism (PCH) cases, and investigate the role of laboratory and clinical findings in predicting TCH. Methods: This retrospective observational multicenter study included patients from 17 pediatric endocrinology centers identified by “National Newborn Screening Program” (NNSP) who were born in 2015 and followed for 6 years. Demographic, clinical, and laboratory information of the cases were compiled through the database http://cedd.saglik-network.org (CEDD-NET). Results: Of the 239 cases initially treated for CH, 128 (53.6%) were determined as transient in whom a trial of levothyroxine (LT4) withdrawal was performed at a median age of 36 (34–38) months. Among the patients with PCH (n = 111), thyroid dysgenesis was diagnosed in 39.6% (n = 44). The predictive factors for TCH were: LT4 dose at the withdrawal of treatment, and initial newborn blood screening (NBS)-TSH level. Based on the receiver operating characteristic (ROC) curve analysis to predict optimal cut-offs for TCH predictors, LT4 dose < 2.0 µg/kg/day at treatment discontinuation was predictive for TCH and was associated with 94.5% specificity and 55.7% sensitivity, with an area under the curve (AUC) of 0.802. The initial NBS-TSH level value < 45 µIU/mL was predictive for TCH with 93.1% specificity and 45.5% sensitivity, with an AUC of 0.641. In patients with eutopic thyroid gland only LT4 dose < 1.1 µg/kg/day at withdrawal time was predictive for TCH with 84.7% sensitivity and 40.4% specificity, with an AUC of 0.750. Conclusion: According to our national follow-up data, the frequency of TCH was 53.6%. We determined the LT4 dose < 2.0 µg/kg/day at discontinuation of treatment and the initial NBS-TSH level < 45 µIU/mL as the best cut-off limits to predict TCH.